Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
Q1 2023 vs. Q4 2022
How the institutions holding Damora Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 22 | 26 | +4 |
| Shares | 8.88M | 8.96M | +83.1K (+0.9%) |
| Value | $10.2M | $17.8M | +$7.63M (+74.7%) |
New holders (5)
Institutions that held Damora Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Trust Co of Toledo NA | 12,000 | $23.9K | 0.00% |
| Citadel Advisors LLC | 4,852 | $9.65K | 0.00% |
| UBS Group AG | 2,484 | $4.94K | 0.00% |
| Northwestern Mutual Wealth Management Co | 1,400 | $2.79K | 0.00% |
| Simplex Trading, LLC | 300 | $0 | 0.00% |
Sold out (1)
Institutions that held Damora Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Arcus Capital Partners, LLC | 484 | $557 |